Last edition
News about "immunotherapy for type 1 diabetes"
UK Approves Sanofi's Teplizumab to Delay Onset of Stage 3 Type 1 Diabetes
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teplizumab (Tzield) to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D.
Immunotherapy For Type 1 Diabetes | 18/08/2025 | By Dineshwori | 103
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members